World's Best Scientists 2026 revealed!
Salvatore Siena

Salvatore Siena

Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
122
Citations
90872
World Ranking
3397
National Ranking
97

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Salvatore Siena is affiliated with the University of Milan in Italy and has a substantial research output in the field of Medicine, focusing primarily on Oncology. Their published work spans over 525 medical publications, with a significant concentration in Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine, and Radiology, Nuclear Medicine and Imaging.

Their research addresses several critical topics in cancer treatment and diagnostics. These topics include:

  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Treatments and Mutations
  • Gastric Cancer Management and Outcomes
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics
  • Genetic factors in colorectal cancer
  • Cancer Immunotherapy and Biomarkers

Salvatore Siena has a consistent publication record in high-impact venues, frequently contributing to:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • ESMO Open
  • Cancer Research
  • Cancers

The following are some recent papers authored or coauthored by Salvatore Siena:

  • Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial, 2021, The Lancet Oncology
  • Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial, 2023, Journal of Clinical Oncology
  • EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer, 2020, Cancer Discovery
  • Precision oncology in metastatic colorectal cancer - from biology to medicine, 2021, Nature Reviews Clinical Oncology
  • Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial, 2022, Nature Medicine

Frequent collaborators in Salvatore Siena's research include:

  • Andrea Sartore-Bianchi
  • Alberto Bardelli
  • Gianluca Mauri
  • Silvia Marsoni
  • Alessio Amatu

Best Publications

  • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

    David Cunningham;Yves Humblet;Salvatore Siena;David Khayat

  • Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

    Chetan Bettegowda;Chetan Bettegowda;Mark Sausen;Rebecca J. Leary;Isaac Kinde

  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

    Rafael G. Amado;Michael Wolf;Marc Peeters;Eric Van Cutsem

  • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Axel Grothey;Eric Van Cutsem;Alberto Sobrero;Salvatore Siena

  • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

    Jean Yves Douillard;Kelly S. Oliner;Salvatore Siena;Josep Tabernero

  • Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

    Eric Van Cutsem;Marc Peeters;Salvatore Siena;Yves Humblet

  • Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

    Federica Di Nicolantonio;Miriam Martini;Francesca Molinari;Andrea Sartore-Bianchi

  • Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

    Sandra Misale;Rona Yaeger;Sebastijan Hobor;Elisa Scala

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • Integrating liquid biopsies into the management of cancer

    Giulia Siravegna;Silvia Marsoni;Salvatore Siena;Alberto Bardelli

  • Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

    Jean Yves Douillard;Salvatore Siena;James Cassidy;Josep Tabernero

  • Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

    Marcia S Brose;Christopher M Nutting;Barbara Jarzab;Rossella Elisei

  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena

  • Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

    Mauro Moroni;Silvio Veronese;Silvia Benvenuti;Giovanna Marrapese

  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial

    Andrea Sartore-Bianchi;Livio Trusolino;Cosimo Martino;Katia Bencardino

  • Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

    Giulia Siravegna;Benedetta Mussolin;Michela Buscarino;Giorgio Corti

  • Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies

    Silvia Benvenuti;Andrea Sartore-Bianchi;Federica Di Nicolantonio;Carlo Zanon

  • A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

    Andrea Bertotti;Giorgia Migliardi;Francesco Galimi;Francesco Sassi

  • GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION

    AlessandroM. Gianni;Marco Bregni;AngelikaC. Stern;Salvatore Siena

  • PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

    Andrea Sartore-Bianchi;Miriam Martini;Francesca Molinari;Silvio Veronese

Frequent Co-Authors

Andrea Sartore-Bianchi
Andrea Sartore-Bianchi University of Milan
Alberto Bardelli
Alberto Bardelli University of Turin
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Marc Peeters
Marc Peeters University of Antwerp
Fortunato Ciardiello
Fortunato Ciardiello University of Campania "Luigi Vanvitelli"
Alfredo Falcone
Alfredo Falcone University of Pisa
Vittorina Zagonel
Vittorina Zagonel Mario Negri Institute for Pharmacological Research
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Takayuki Yoshino
Takayuki Yoshino University of Tsukuba

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always mean becoming a physician. The healthcare field offers a variety of online degree programs and certifications that can open doors to rewarding roles with flexibility and growth potential.

For those interested in healthcare data and technology, online RHIT degree programs provide a pathway into health information management, ensuring patient records are accurate and secure. If you prefer working with medical data but not directly with patients, medical coding certification online can help you quickly enter the workforce in an essential, in-demand role.

For clinical positions, nursing remains a cornerstone of healthcare. Many students are pursuing advanced nursing degrees through the cheapest online acute care nurse practitioner programs or earning an MSN online using the cheapest online MSN programs. These programs allow for specialized training and leadership opportunities, often with flexible schedules suitable for working professionals.

Exploring these online options can help you tailor your healthcare career to your interests, lifestyle, and long-term goals.

Best Scientists Citing Salvatore Siena

Trending Scientists

Recently Published Articles